O’Melveny & Myers LLP represented Dicerna Pharmaceuticals, Inc., an emerging pharmaceutical company developing RNA interference-based therapeutics against genetically defined targets in multiple disease areas, in a Series C preferred stock financing in which Dicerna raised US$60 million.
The O’Melveny team was led by Jennifer DePalma, Ruchun Ji, and Sam Zucker.
Related Posts:
- O’Melveny Represents Cytomx Therapeutics in Expansion of Series B Financing
- O’Melveny Represents Celsion in Registered Direct Offering
- O’Melveny Represents Investors in US$40 Million Series A Convertible Preferred Stock Financing with Alimera Sciences
- O’Melveny Represents Progenics Pharmaceuticals in Proposed Public Offering
- O’Melveny Represents Synacor in Formation of Joint Venture with Maxit Technology